Rusan Pharma Achieves USFDA GMP Approval for Ankleshwar API Facility

Rusan Pharma Private Limited, a leading Indian pharmaceutical company specializing in addiction treatment and pain management, has received Good Manufacturing Practice (GMP) approval from the USFDA for its Active Pharmaceutical Ingredient (API) facility in Ankleshwar, Gujarat. This significant milestone allows Rusan to expand its portfolio and enter the US API market.

Rusan Pharma, an Indian pharmaceutical leader in addiction treatment and pain management, has announced the securing of Good Manufacturing Practice (GMP) approval from the USFDA for its API facility in Ankleshwar, Gujarat.

This milestone enables Rusan Pharma to tap into the US API market, expanding its product portfolio to include niche APIs and enhancing its global presence. Dr. Kunal Saxena, Rusan Pharma's Managing Director, emphasized the importance of this approval, citing it as a testament to their commitment to quality and manufacturing excellence.

Rusan's facility has already received GMP approvals from other international agencies and showcases the company's move towards innovative, paperless manufacturing solutions. The approval will bolster Rusan's ability to supply high-quality APIs to various markets and underscores their strategic role in global pharmaceutical manufacturing.

(With inputs from agencies.)